Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
24.51
+1.28 (5.51%)
Jan 22, 2026, 3:54 PM EST - Market open
Centessa Pharmaceuticals Revenue
Centessa Pharmaceuticals had revenue of $15.00M in the twelve months ending September 30, 2025, up 118.88% year-over-year.
Revenue (ttm)
$15.00M
Revenue Growth
+118.88%
P/S Ratio
206.38
Revenue / Employee
$194,805
Employees
77
Market Cap
3.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 6.85M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Corcept Therapeutics | 741.17M |
| Tarsus Pharmaceuticals | 366.10M |
| Arcutis Biotherapeutics | 317.93M |
| IDEAYA Biosciences | 214.83M |
| Viridian Therapeutics | 70.79M |
| Liquidia | 69.22M |
| Beam Therapeutics | 55.70M |
| NewAmsterdam Pharma Company | 35.24M |
CNTA News
- 7 days ago - Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting - GlobeNewsWire
- 9 days ago - Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa - GlobeNewsWire
- 6 weeks ago - Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program - GlobeNewsWire
- 5 months ago - Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewsWire